Popular Articles
Revitol Cellulite Cream

Quality Data Made Accessible To Clinical Teams
NHS clinical teams will have access to data showing their performance against a set of more than 200 indicators of high quality care in the NHS in one place. It is the next phase in the drive to help NHS professionals improve the quality of care they deliver to patients, and will also support providers and commissioners of NHS services. Don't forget to buy zoloft online no prescription.

Covidien Announces Health Canada Approval For Its Generic Myocardial Perfusion Imaging Kit
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Health Canada has approved the Company"s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien"s generic product is fully substitutable for Cardiolite®, a myocardial perfusion imaging agent used for detecting coronary artery disease.

generic viagra online


News of the day
Amarillo Biosciences Announces Completion Of Screening Process For Influenza Study In Australia
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that the screening of volunteers for inclusion in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia is now complete. The investigators met their target of screening at least 200 healthy adults for participation in the trial. A total of 215 volunteers were evaluated and 134 of them have been enrolled into the study to date. About 90% of the screened subjects have been found to qualify for the study, so additional enrollments are expected over the next 2 weeks to bring the total number of study participants up to or above the targeted 160 subjects.
Mental Health

QualityMetric Offers Way To Measure The Impact Of Sleep Problems On Individuals And Groups

There are few things as vital to health and well-being as a good night"s sleep. Yet millions of us -- nearly 50 million according to the National Sleep Foundation -- suffer from chronic sleep problems or disorders. Every year, more and more scientific studies are showing correlations between poor or insufficient sleep and disease. Now there is a simple, easy way to quantify and measure sleep problems with patient populations. The MOS Sleep Scale was originally developed in the Medical Outcomes Study (MOS), a four-year observational study of the health outcomes for chronically ill patients. The MOS Sleep Scale measures six dimensions of sleep, including initiation, maintenance (e.g. staying asleep), quantity, adequacy, somnolence (e.g. drowsiness), and respiratory impairments (e.g. shortness of breath, snoring). Disturbed sleep has a major impact on quality of life and is often a common symptom of many other chronic conditions, such as chronic pain and mood disorders. "According to a new study by Marketdata, sleep is a $23.7 billion-a-year industry in the United States," reports Jeff Hallowell, Vice President of Business Development at QualityMetric. "Measuring the impact of sleep problems, as well as demonstrating the effectiveness of products developed to alleviate sleep disorders, can be a very valuable tool for pharmaceutical manufacturers, public health officials, and healthcare providers." QualityMetric distributes translations of two versions of the MOS Sleep Scale: a 12 question version and a six question version. The 12 question version is available in 85 language translations and the six question version is available in 61 language translations. The forms have a standard four-week recall period. The reliability and validity of the MOS Sleep Scale have been evaluated in a number of disease areas, including neuropathic pain, restless leg syndrome, overactive bladder, and rheumatoid arthritis. It has also been evaluated in the general U.S. population. A recent literature search yielded 80 citations in which the MOS Sleep Scale had been used, including 14 clinical trials. About QualityMetric Incorporated: QualityMetric works with the world"s largest healthcare and life sciences companies to measure health outcomes. Our products help market new drugs and biologics, track health improvement or decline, screen populations for disease, and identify future health risks. QualityMetric"s patient-reported outcome(PRO) surveys provide scientifically valid assessments of both physical and mental health. Our PROs include the SF-36v2(R), SF-12v2(R), and SF-8(TM) Health Surveys, SF-10(TM) Health Survey for Children, Asthma Control Test(TM) (ACT(TM)), Pain Impact Questionnaire(TM) (PIQ-6(TM)), and DYNHA(R) Dynamic Health Assessments. Our Outcomes Insight Consulting(TM) Division can develop customized PROs and provide in-depth analysis of the results. QualityMetric"s founder and Chief Science Officer, John E. Ware, Jr., PhD is a thought-leader in the field of psychometrics and health outcome measurement. QualityMetric Incorporated


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):